Barclays analyst Carter Gould lowered the firm’s price target on Pfizer to $38 from $40 and keeps an Equal Weight rating on the shares ahead of the Q2 results. The analyst sees “poor” investor sentiment into a “mixed-quarter with few clean beats” for U.S. pharmaceuticals. Eli Lilly (LLY) and Neurocrine Biosciences (NBIX) are the best positioned into the Q2 prints, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- B. Riley biotechnology analysts to hold an analyst/industry conference call
- Pfizer among big pharma stocks on sale right now, Barron’s says
- Pfizer, Arvinas and Carrick Therapeutics collaborate for oncological combination
- Caribou Biosciences announces $25M investment from Pfizer
- Former Pfizer statistician charged by SEC with insider trading